Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.
...
Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.
Henry Ford West Bloomfield Hospital, Bloomfield Hills, Michigan, United States
University of Texas Health Science Center, Houston, Department of Neurology, Houston, Texas, United States
Center for Neurological Care and Research, San Antonio, Texas, United States
Rambam Health Care Campus, Haifa, Israel
Spaulding Rehabilitation Hospital, Boston, Massachusetts, United States
Oregon Health and Science University, Portland, Oregon, United States
Service de Neurologie, Toulouse, France
Department of Neurology, Oregon Health and Science University, Mail Code OP32, 3181 SW Sam Jackson Park Road, Portland, Oregon, United States
Psychiatry Service, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.